EUVIMEDEUVIMED entdecken
Crossref

Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation

Selai Akseer iD, Shant Torkom Yeretzian iD, Lusine Abrahamyan iD, Martine Puts iD, Mostafa Mohamed iD, Wee Kheng Soo iD, Shabbir M H Alibhai iD, Yeva Sahakyan iD

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-00248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Selai Akseer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Neoplasms, Geriatric Assessment, Models, Economic, Health Care Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Geriatric assessment and management (GAM) is a guideline-recommended strategy for optimizing cancer management among older adults. A recent cost-utility analysis of the Canadian 5C randomized controlled trial (RCT) found GAM to be cost effective for selected groups. This study aimed to assess the cost-utility of GAM plus usual care (UC) versus UC alone in older adults with cancer using a decision model and best available evidence from four international RCTs—GAIN, GAP70, INTEGERATE, and 5C. METHODS For the model, we used pooled data from four RCTs and peer-reviewed literature. Deterministic and probabilistic analyses were performed from the Canadian health care payer perspective, applying a 6-month time horizon. Sensitivity analyses included per-trial scenario analyses, 1-year time horizon, and US health care payer perspective. We reported costs per quality-adjusted life year (QALY) and incremental net monetary benefit (INMB). RESULTS The base-case analysis indicated that GAM had an INMB of $599 in Canadian dollars (CAD; 95% credibility interval, –$3,428 to $4,742) with 60.9% probability of being cost effective at a threshold of $50,000 (CAD) per QALY. Trial-specific results varied, with the GAP70 and INTEGERATE trials yielding positive INMB ($2,231 [CAD] and $2,104 [CAD], respectively), suggesting cost-effectiveness, whereas 5C and GAIN resulted in negative INMB (–$489 [CAD] and –$234 [CAD], respectively). Chemotherapy and hospitalization costs were the main driver of costs in both strategies. CONCLUSION GAM is overall cost effective, with results varying across trial scenarios due to differences in chemotherapy dose intensity, hospitalization rates, and associated costs. Future research should prioritize identifying optimal core GAM components, delivery mode, and patient selection criteria to enhance its effectiveness and cost-effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsGeriatric AssessmentModels, EconomicHealth Care CostsHumansCost-Benefit AnalysisAgedQuality-Adjusted Life YearsCanadaAged, 80 and overFemaleMaleRandomized Controlled Trials as Topic

Autor:innen und Institutionen

  • Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada.
  • Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
  • Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, ON, Canada.
  • Lawrence Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada.
  • Department of Public Health Sciences, University of Rochester, Rochester, NY.
  • Department of Medicine, University of Rochester, Rochester, NY.

ORCID-Profile: Selai Akseer, Shant Torkom Yeretzian, Lusine Abrahamyan, Martine Puts, Mostafa Mohamed, Wee Kheng Soo, Shabbir M H Alibhai, Yeva Sahakyan

Zitieren

APA

Akseer, S., Yeretzian, S. T., Abrahamyan, L., Puts, M., Mohamed, M., Soo, W. K., Alibhai, S. M. H., & Sahakyan, Y. (2026). Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00248

Vancouver

Akseer S, Yeretzian ST, Abrahamyan L, Puts M, Mohamed M, Soo WK, et al. Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-00248

BibTeX
@article{Akseer2026,
  author = {Akseer, Selai and Yeretzian, Shant Torkom and Abrahamyan, Lusine and Puts, Martine and Mohamed, Mostafa and Soo, Wee Kheng and Alibhai, Shabbir M H and Sahakyan, Yeva},
  title = {Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-00248}
}
Kostenlos starten →